In vivo assessment of the combination of the JAK1 selective inhibitor itacitinib with first- and second-generation EGFR inhibitors in models of non-small cell lung cancer

被引：2
|
作者：
Stubbs, Matthew C. [1 ]
Wen, Xiaoming [1 ]
Xue, Chu-Biao [1 ]
Huang, Taisheng [1 ]
Yao, Wenqing [1 ]
Metcalf, Brian [1 ]
Huber, Reid [1 ]
Scherle, Peggy [1 ]
Ruggeri, Bruce [1 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2938
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2938
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
    Wang, Shouzheng
    Li, Junling
    ONCOTARGETS AND THERAPY, 2019, 12 : 6535 - 6548
  • [2] Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer
    Ding, Q.
    Shao, Y.
    Wu, X.
    Hu, Q.
    Meng, Q.
    Yin, J. C.
    Ou, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S580 - S580
  • [3] Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth
    Xie, Xiaomeng
    Wang, Xiangyu
    Shi, Xiaodan
    Zhang, Yuanyuan
    Laster, Kyle Vaughn
    Liu, Kangdong
    Dong, Zigang
    Kim, Dong Joon
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (05) : 2645 - 2654
  • [4] First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)
  • [5] Clinical outcome analysis of different first- and second-generation EGFR-tyrosine kinase inhibitors in untreated patients with EGFR-mutated non-small cell lung cancer with baseline brain metastasis
    Hsu, Chen-Chuan
    Chiu, Li-Chung
    Ko, How-Wen
    Wu, Chiao-En
    Kuo, Scott Chih-Hsi
    Ju, Jia-Shiuan
    Huang, Allen Chung-Cheng
    Wang, Chin-Chou
    Yang, Cheng-Ta
    Hsu, Ping-Chih
    ONCOLOGY LETTERS, 2025, 29 (04)
  • [6] Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
    Wang, Xinwen
    Zhang, Fupeng
    Yang, Xi
    Xue, Meiping
    Li, Xiaoli
    Gao, Yu
    Liu, Likun
    ONCOLOGY RESEARCH, 2019, 27 (08) : 871 - 877
  • [7] Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation
    Nishimura, Tadashi
    Okano, Tomohito
    Naito, Masahiro
    Iwanaka, Souichi
    Ohiwa, Ayaka
    Sakakura, Yasumasa
    Yasuma, Taro
    Fujimoto, Hajime
    D'Alessandro-Gabazza, Corina N.
    Oomoto, Yasuhiro
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Ibata, Hidenori
    THORACIC CANCER, 2021, 12 (07) : 1067 - 1073
  • [8] Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer
    Mukherji, Deborah
    Spicer, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (03) : 293 - 301
  • [9] First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
    Huang, Allen Chung-Cheng
    Huang, Chi-Hsien
    Ju, Jia-Shiuan
    Chiu, Tzu-Hsuan
    Tung, Pi-Hung
    Wang, Chin-Chou
    Liu, Chien-Ying
    Chung, Fu-Tsai
    Fang, Yueh-Fu
    Guo, Yi-Ke
    Kuo, Chih-Hsi Scott
    Yang, Cheng-Ta
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [10] Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA
    Otsubo, Kohei
    Sakai, Kazuko
    Takeshita, Masafumi
    Harada, Daijiro
    Azuma, Koichi
    Ota, Keiichi
    Akamatsu, Hiroaki
    Goto, Koichi
    Horiike, Atsushi
    Kurata, Takayasu
    Nakagaki, Noriaki
    Nosaki, Kaname
    Iwama, Eiji
    Nakanishi, Yoichi
    Nishio, Kazuto
    Okamoto, Isamu
    ONCOLOGIST, 2019, 24 (08): : 1022 - 1026
12345